Camurus Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Camurus ha aumentado sus beneficios a una tasa media anual de 67.2%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 10.4% anual. Los ingresos han ido creciendo a una tasa media de 54.1% al año. La rentabilidad financiera de Camurus es de 28.9%, y sus márgenes netos son de 25.1%.

Información clave

71.8%

Tasa de crecimiento de los beneficios

72.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	30.5%
Tasa de crecimiento de los ingresos	52.2%
Rentabilidad financiera	17.0%
Margen neto	24.7%
Próxima actualización de resultados	16 Jul 2024

Actualizaciones de resultados anteriores recientes

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Feb 22

Recent updates

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

May 02

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Nov 11

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Feb 22

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Apr 30

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Dec 09

Companies Like Camurus (STO:CAMX) Can Afford To Invest In Growth

Sep 09

Desglose de ingresos y gastos

Cómo gana y gasta dinero Camurus. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

OM:CAMX Ingresos, gastos y beneficios (SEK Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	1,823	450	449	718
31 Dec 23	1,717	431	424	638
30 Sep 23	1,610	460	383	543
30 Jun 23	1,468	408	356	502
31 Mar 23	1,020	115	330	457
31 Dec 22	956	56	309	474
30 Sep 22	871	28	289	445
30 Jun 22	784	-13	268	422
31 Mar 22	695	-69	249	423
31 Dec 21	601	-90	240	389
30 Sep 21	523	-142	275	355
30 Jun 21	470	-156	285	319
31 Mar 21	413	-128	275	252
31 Dec 20	336	-167	269	239
30 Sep 20	265	-174	214	229
30 Jun 20	205	-216	197	246
31 Mar 20	136	-284	198	263
31 Dec 19	106	-290	194	249
30 Sep 19	78	-305	192	248
30 Jun 19	58	-286	168	235
31 Mar 19	53	-266	145	225
31 Dec 18	49	-235	123	208
30 Sep 18	47	-200	100	194
30 Jun 18	40	-208	93	205
31 Mar 18	52	-187	80	206
31 Dec 17	54	-191	72	223
30 Sep 17	86	-166	64	234
30 Jun 17	104	-127	55	209
31 Mar 17	111	-102	49	191
31 Dec 16	114	-81	43	172
30 Sep 16	113	-85	29	154
30 Jun 16	120	-95	26	156
31 Mar 16	116	-189	31	151
31 Dec 15	155	-160	31	153
30 Sep 15	263	-53	42	153
31 Dec 14	208	48	34	114
31 Dec 13	198	99	22	53

Ingresos de calidad: CAMX tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (25.1%) de CAMX son superiores a los del año pasado (5.8%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CAMX ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 67.2% al año.

Acelerando crecimiento: El crecimiento de los beneficios de CAMX en el último año (676.6%) supera su media de 5 años (67.2% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de CAMX en el último año (676.6%) superó al de la industria Pharmaceuticals 3.8%.

Camurus Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings released: EPS: kr1.36 (vs kr1.06 in 1Q 2023)

Full year 2023 earnings: EPS misses analyst expectations

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot (Cam2029) for the Treatment of Acromegaly

Chief Technology Officer recently sold kr845k worth of stock

Consensus EPS estimates increase by 18%

First quarter 2024 earnings released: EPS: kr1.36 (vs kr1.06 in 1Q 2023)

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Camurus AB (Publ) Announces Board Resignations

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB (Publ) Announces FDA Acceptance of NDA Submission for Oclaiz™ for Treatment of Acromegaly

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Consensus EPS estimates fall by 39%

With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB Provides Earnings Guidance for the Full Year 2024

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

Camurus AB (Publ) Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease

Investor sentiment deteriorates as stock falls 15%

Price target increased by 8.2% to kr550

Camurus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.09 billion.

Camurus AB (publ) Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly

Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected

President exercised options to buy kr86m worth of stock.

Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors

Price target increased by 16% to kr471

Investor sentiment improves as stock rises 20%

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Camurus AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.1% to kr351

Camurus AB (Publ) Raises Earnings Guidance for the Year 2023

Camurus AB (publ), Annual General Meeting, May 08, 2024

Insider recently sold kr295k worth of stock

Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn

Camurus AB (Publ) Provides Earnings Outlook for the Year 2023

New major risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot (Cam2029) in Patients with Acromegaly

Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly

President recently sold kr23m worth of stock

Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder

Consensus EPS estimates increase by 21%

Consensus EPS estimates increase by 25%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (Publ) Elects Erika Söderberg Johnsson as Board Member

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Price target decreased by 7.3% to kr287

Third quarter 2022 earnings released: EPS: kr0.63 (vs kr0.11 loss in 3Q 2021)

Consensus EPS estimates increase by 17%

Camurus AB (Publ) Provides Earnings Guidance for the Year 2023

Consensus forecasts updated

Camurus Announces PDUFA Date for Brixadi NDA for the Treatment of Opioid Use Disorder in the US

Forecast to breakeven in 2022

Price target increased to kr305

Camurus AB (Publ) Provides Earnings Guidance for the Year 2022

Price target increased to kr283

Camurus AB (publ), Annual General Meeting, May 10, 2023

Camurus AB (publ) to Report Fiscal Year 2022 Final Results on Mar 30, 2023

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Camurus AB (Publ) Raises Operating Result Guidance for the Full Year 2022

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX).

Vice President exercised options and sold kr178k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Camurus AB (Publ) Elects Stefan Persson as New Board Member

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Full year 2021 earnings: EPS and revenues miss analyst expectations

Camurus AB (Publ) Provides Earnings Guidance for the Fiscal Year 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (Publ) Provides Earnings Guidance for the Fiscal Year 2022

Camurus Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Pants with Genetic Obesity Disoisorder